The Human Foundation of Next-Generation Medicine
Neurxstem develops the only patented human brain models capable of generating regulator-grade molecular data for diagnostics, therapeutics, and predictive AI. The platform combines human biology, functional genomics, and high-precision metabolomics, delivering 98% reproducibility and direct concordance with postmortem tissue.
Built in 2015—years ahead of current regulatory standards—the models map and modulate the molecular drivers of Alzheimer’s, Parkinson’s, aging, migraine, autism, and opioid use disorder. They provide the human accuracy that rodent systems cannot.
Neurxstem now operates as a human-data layer for diagnostic development, therapeutic discovery, and next-generation AI health systems, grounded in precision and regulator-aligned evidence.
Our Patented Neural Organoid Platform underpins all of our precision brain medicine applications.
PATENTED NEURAL ORGANOID PLATFORM
Complete human brain architecture: retina, cortex, midbrain, hindbrain, cerebellum, spinal cord, and BBB.
Contains neurons, astrocytes, oligodendrocytes, vascular endothelial cells, and microglia.
Generates high-precision transcriptomic and metabolomic datasets with 98–99% reproducibility.
Only issued U.S. patent covering functional genomic human brain models.
MEDICAL
Human-validated molecular evidence for Alzheimer’s, Parkinson’s, aging, migraine, autism, and opioid use disorder.
Early diagnostics and companion biomarkers aligned with FDA human-data requirements.
Mechanism-of-action validation and target identification using direct human concordance.
IND-supportive datasets already validated by NIH and DoD.
LONGEVITY
Patented human progeria-based accelerated aging models replicating the “hallmarks of aging.”
Molecular signatures for healthy aging, fragility, resilience, and intervention discovery.
Pathways for senescence, inflammation, glymphatic function, and neuroimmune aging.
Foundation for cosmeceutical, wellness, and preventive health applications.
AI
Multi-omic, regulator-grade data for AI learning, reasoning, and predictive modeling.
Enables prodromal disease tracking 20–40 years before symptoms emerge.
Supports digital twins, early warning systems, and high-fidelity predictive healthcare models.
Resolves AI’s core bottleneck: lack of precise data (noisy EHR data replaced by molecular truth).
Built on First Principles of Human Biology
Animal models cannot replicate the human brain.
Neurxstem can.
Our patented neural organoid technology recreates major regions and cell types of the human brain with molecular fidelity unmatched in neuroscience. Each model generates complete transcriptomic, metabolomic, and phenotypic signatures providing the clarity needed to understand mechanisms, identify targets, and reverse disease.
Validated by Peer Review and Federal Research Programs
Our work has been validated through independent federally funded research programs and peer-reviewed scientific studies. The platform’s molecular signatures, disease models, and reproducibility metrics were developed and corroborated through NIH and Department of Defense-supported projects.
Our datasets align with the FDA Modernization Act requirement for human-relevant evidence, reflecting a decade of regulator-consistent development.